Roche to Speed Up Obesity Market Entry to Catch Up With Rivals, FT Reports
Provided by
Dow Jones
--Roche Holding aims to accelerate its anti-obesity drugs to compete with rivals Eli Lilly and Novo Nordisk after positive results of its obesity pill candidate in an early-stage clinical trial, its Chief Executive Thomas Schinecker told the Financial Times.
--The Swiss pharma company executive said its weight-loss drugs could enter the market earlier than expected, potentially by 2028, the FT reports.
--Schinecker said its $3-billion-plus purchase of Carmot Therapeutics could lead to around seven weight-loss treatments, according to the FT.
Full story: https://on.ft.com/3SpRwDr
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
July 29, 2024 02:06 ET (06:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
United States